Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Future studies for the combination of 177Lu-PSMA-617 and olaparib

Shahneen Sandhu • 4 Jun 2023
ASCO 2023
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Olaparib PARP inhibitors

Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, states that discussions with pharmaceutical companies are taking place relating to the possibility of a larger randomized trial to evaluate the combination of 177Lu-PSMA-617 and olaparib versus 177Lu-PSMA-617 monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shahneen Sandhu

1:06
The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer
Shahneen Sandhu • 4 Jun 2023
1:24
LuPARP: 177Lu-PSMA-617 and PARP inhibitor combination for prostate cancer
Shahneen Sandhu • 4 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals